[Featured Stock] Curatis Hits Upper Limit on First Day of KOSDAQ Listing

46% Increase Compared to the Offering Price of 4,000 Won

Vaccine specialist company Curatis soared to the upper price limit on its first day of listing on the KOSDAQ.

At 10:20 a.m. on the 15th, Curatis's stock price was 5,850 won, up 30% (upper limit) from the opening price of 4,500 won. Compared to the public offering price of 4,000 won, it rose more than 46%. Despite low interest from institutions during the IPO process, the stock showed strength on its first day of listing.

Curatis showed a low demand ratio of 52.89 to 1 in the institutional book-building held on the 30th and 31st of last month. The public offering price was also set lower than Curatis's proposed price band of 6,500 to 8,000 won. In the general subscription, it recorded a competition rate of 155 to 1, with about 270 billion won raised in subscription deposits.

Curatis, established in 2016, is a company specializing in the development of vaccines and immune enhancers. Its main product is ‘QTP101,’ a tuberculosis vaccine for adults and adolescents. Last year, it recorded sales of 8.4 billion won, an operating loss of 21.8 billion won, and a net loss of 35.7 billion won.

This content was produced with the assistance of AI translation services.